Eikon Therapeutics
Eikon Therapeutics raises $106M Series C at $1B valuation
Quick Facts
Eikon Therapeutics: Series C Funding Round
Eikon Therapeutics has successfully raised $106M in Series C funding, reaching a valuation of $1B.
Company Overview
Biotech startup developing cancer-fighting therapeutic assets
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Two Sigma Ventures.
Company Information
- Headquarters: Hayward, CA
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Eikon Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Two Sigma Ventures: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...